Terms: = Ovarian cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Treatment
9644 results:
1. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
[TBL] [Abstract] [Full Text] [Related]
2. Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study.
Schlootz S; Saner FAM; Rabaglio M; Imboden S; Wampfler J
Swiss Med Wkly; 2024 Apr; 154():3386. PubMed ID: 38754016
[TBL] [Abstract] [Full Text] [Related]
3. Enhanced anti-tumor efficacy with multi-transgene armed mesenchymal stem cells for treating peritoneal carcinomatosis.
Ho YK; Woo JY; Loke KM; Deng LW; Too HP
J Transl Med; 2024 May; 22(1):463. PubMed ID: 38750559
[TBL] [Abstract] [Full Text] [Related]
4. The Role of Palliative Surgery in the Management of Acute Intestinal Obstruction Secondary to Peritoneal Carcinomatosis.
Bhat BK; Yadav A; Nundy S
Chirurgia (Bucur); 2024 Apr; 119(2):218-226. PubMed ID: 38743835
[No Abstract] [Full Text] [Related]
5. Tailoring postoperative management through sentinel lymph node biopsy in low- and intermediate-risk endometrial cancer - the SENTRY clinical trial.
Sorokin P; Novozhilov M; Utkin D; Abduragimova Z; Dudina I; Nikiforchin A; Kulikova S
Klin Onkol; 2024; 38(2):126-133. PubMed ID: 38697821
[TBL] [Abstract] [Full Text] [Related]
6. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
7. Cardiovascular mortality risk in patients with ovarian cancer: a population-based study.
Hu ZL; Yuan YX; Xia MY; Li Y; Yang Y; Wang SN; Meng XZ; Sun MY; Wang N
J Ovarian Res; 2024 Apr; 17(1):88. PubMed ID: 38664732
[TBL] [Abstract] [Full Text] [Related]
8. Granulosa cell tumor of the ovary: a series of 6 cases.
da Costa REAR; Silva MCA; Cavalcante ECX; Branco ROC; Dos Reis CA; Vieira SC
Pan Afr Med J; 2024; 47():58. PubMed ID: 38646138
[TBL] [Abstract] [Full Text] [Related]
9. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
10. Small bite fascial closure technique reduces incisional hernia rates in gynecologic oncology patients.
Straubhar AM; Stroup C; Manorot A; McCool K; Rolston A; Reynolds RK; McLean K; de Bear O; Siedel J; Uppal S
Int J Gynecol Cancer; 2024 May; 34(5):745-750. PubMed ID: 38642924
[TBL] [Abstract] [Full Text] [Related]
11. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
12. Imaging for local recurrence of breast cancer.
Schlaiss T; Bott L; Herbert SL; Bartmann C; Kiesel M; Salmen J; Sauer ST; Christner SA; Petritsch B; Grunz JP; Woeckel A; Löb S; Diessner J
J Cancer Res Clin Oncol; 2024 Apr; 150(4):200. PubMed ID: 38627285
[TBL] [Abstract] [Full Text] [Related]
13. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
[TBL] [Abstract] [Full Text] [Related]
14. Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine.
Elshami M; Jaber I; Alser M; Al-Slaibi I; Jabr H; Ubaiat S; Tuffaha A; Khader S; Khraishi R; Arafeh ZA; Al-Madhoun S; Alqattaa A; Yaseen A; El Hadi AA; Barhoush O; Hijazy M; Eleyan T; Alser A; Hziema AA; Shatat A; Almakhtoob F; Mohamad B; Farhat W; Abuamra Y; Mousa H; Adawi R; Musallam A; Albarqi SI; Abu-El-Noor N; Bottcher B
BMC Public Health; 2024 Apr; 24(1):1027. PubMed ID: 38609950
[TBL] [Abstract] [Full Text] [Related]
15. Olaparib Addition to Maintenance Bevacizumab Therapy in ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC; Schmidt S; Becker K; Thiele H; Nürnberg P; Richters L; Ernst C; Treilleux I; Medioni J; Heitz F; Pisano C; Garcia Y; Petru E; Hietanen S; Colombo N; Vergote I; Nagao S; Linn SC; Pujade-Lauraine E; Ray-Coquard I; Harter P; Hahnen E; Schmutzler RK
JAMA Netw Open; 2024 Apr; 7(4):e245552. PubMed ID: 38592722
[TBL] [Abstract] [Full Text] [Related]
16. Salpingectomy for ectopic pregnancy reduces ovarian cancer risk-a nationwide study.
Yen JC; Wu TI; Stone R; Wang TL; Visvanathan K; Chen LY; Hsu MH; Shih IM
JNCI Cancer Spectr; 2024 Apr; 8(3):. PubMed ID: 38588567
[TBL] [Abstract] [Full Text] [Related]
17. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
18. Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer.
Kallio HM; Savolainen K; Virtanen T; Ryyppö L; Selin H; Martikainen P; Staff S; Kivinummi K; Sipola J; Vuorinen J; Nikkola J; Nykter M; Auranen A; Annala M
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38580393
[TBL] [Abstract] [Full Text] [Related]
19. Patient Location and Disparities in Access to Fertility Preservation for Women With Gynecologic or Breast cancer.
Kanbergs A; Jorgensen K; Agusti N; Viveros-Carreño D; Wu CF; Nitecki R; Harris JA; Woodard T; Ramphul R; Rauh-Hain JA
Obstet Gynecol; 2024 Jun; 143(6):824-834. PubMed ID: 38574368
[TBL] [Abstract] [Full Text] [Related]
20. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
[TBL] [Abstract] [Full Text] [Related]
[Next]
